NCT01755442View on ClinicalTrials.gov

Investigate Effect of AMG 151 on 24-hour Ambulatory Blood Pressure & Glucose Levels in Type 2 Diabetes Mellitus Subjects

PHASE1TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions
Diabetes Mellitus
Interventions
OTHER

Placebo

Eligible subjects will be randomly assigned (1:1) to receive AMG 151 and matching placebo in 1 of 2 sequences over 2 treatment periods.

DRUG

AMG 151

Eligible subjects will be randomly assigned (1:1) to receive AMG 151 and matching placebo in 1 of 2 sequences over 2 treatment periods.

Trial Locations (1)

92161

Research Site, San Diego

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY